About
Cancer immunotherapy, RNAi
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapySouthwestern U.S.
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
15
As Collaborator
1
Total Enrollment
379
By Phase
PHASE3: 1PHASE2: 10PHASE1: 4
By Status
COMPLETED: 10TERMINATED: 3WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1TEMPORARILY_NOT_AVAILABLE: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT03495921Lead Sponsor
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
PHASE3Terminated
32 participants
Started: Aug 21, 2018 · Completed: Jan 20, 2022
NCT03073525Lead Sponsor
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
PHASE2Completed
25 participants
Started: May 31, 2017 · Completed: May 18, 2022
NCT02736565Lead Sponsor
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
PHASE1Completed
7 participants
Started: Oct 31, 2016 · Completed: Aug 4, 2020
NCT02725489Collaborator
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
PHASE2Completed
13 participants
Started: Jun 3, 2016 · Completed: Dec 2, 2020
NCT02639234Lead Sponsor
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
PHASE2Withdrawn
Started: Mar 31, 2016 · Completed: Mar 31, 2017
Locations (1)
Headquarters
Carrollton, TX, United States
Map
Loading map...